Telaprevir vs boceprevir in hepatitis C patients with advanced fibrosis and/or compensated cirrhosis

Trial Profile

Telaprevir vs boceprevir in hepatitis C patients with advanced fibrosis and/or compensated cirrhosis

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2013

At a glance

  • Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Nov 2013 New trial record
    • 16 Oct 2013 Results presented at the 78th Annual Scientific Meeting of the American College of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top